Press

News, updates, and media resources from Medical 21.

Press Releases →

In The News →

Media Kit →

Press Contact →

Press Releases

Featured
Medical 21, Inc. Announces Approval to Begin Human Clinical Studies in Spain
Medical 21, Inc. Announces Approval to Begin Human Clinical Studies in Spain

Medical 21, Inc. , a medical technology company focused on reshaping the future of cardiac bypass surgery, announced today that the Company has received approval to begin human clinical studies on the MAVERICS graft in Spain.

Read more →

In The News

Featured
After founding device companies worth billions, Manny Villafaña says his newest will be bigger than all of them combined
After founding device companies worth billions, Manny Villafaña says his newest will be bigger than all of them combined

Manny Villafaña says his latest medical device will be “the single biggest product ever developed to be put in the human body.”

Source: www.medicaldesignandoutsourcing.com

Read more →
Synthetic regenerative graft developer Medical 21 files for a $25 million IPO
Synthetic regenerative graft developer Medical 21 files for a $25 million IPO

Medical 21, which is developing a synthetic regenerative graft for coronary bypass surgery, filed on Thursday with the SEC to raise up to $25 million in an initial public offering.

Source: https://www.renaissancecapital.com/

Read more →
First-in-human trial of regenerative coronary bypass graft to commence
First-in-human trial of regenerative coronary bypass graft to commence

Medical 21 has received regulatory approval in Spain under the European Union Medical Device Regulation (EU MDR) to initiate the company’s first-in-human, multicentre clinical trial of the Maverics graft—a novel regenerative small-diameter coronary bypass graft—the MAVERICS coronary revascularization study.

Source: Cardiovascular News

Read more →
Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain

Regulatory clearance enables launch of the MAVERICS Coronary Revascularization Study, advancing evaluation of the Company's next-generation synthetic small-diameter bypass graft.

Source: Yahoo Finance

Read more →
08:43 ET Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
08:43 ET Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain

Medical 21, Inc. has received regulatory approval in Spain to initiate its first-in-human clinical trial for the MAVERICS Coronary Revascularization Study. This study will evaluate the company's next-generation regenerative small-diameter coronary bypass graft, designed to improve coronary artery bypass grafting (CABG) procedures. The MAVERICS graft aims to provide a durable alternative to harvested vessels, enhancing patient outcomes. This approval marks a significant milestone for Medical 21 in advancing its mission to transform coronary bypass surgery.

Source: Longbridge

Read more →
Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain

Regulatory clearance enables launch of the MAVERICS Coronary Revascularization Study, advancing evaluation of the Company's next-generation synthetic small-diameter bypass graft.

Source: Morningstar

Read more →

Media Kit

 

Press Contact

Andrea Sweeney
VP Business Administration
406429@email4pr.com
+1-612-429-7630

3700 Annapolis Lane North #105
Plymouth, MN 55447

Contact Us